This post is from a suggested group
The Evolution of Oncology Therapeutics
The development of drugs for cancer treatment has undergone a profound transformation, moving from non-specific cytotoxic chemotherapy to highly targeted and personalized therapeutics. Early approaches aimed to kill rapidly dividing cells but often resulted in severe systemic side effects. Today, the focus is on understanding the molecular and genetic underpinnings of an individual’s tumor, leading to the creation of compounds designed to interfere with specific signaling pathways or genetic alterations unique to the cancerous cells. This paradigm shift has significantly improved both survival rates and the quality of life for many patients battling various forms of malignancy.
Two key advancements define the modern era of oncology treatment: targeted therapies and immunotherapy. Targeted therapies, such as tyrosine kinase inhibitors, block the activity of specific proteins that drive uncontrolled cell growth, often sparing healthy tissue. Immunotherapy, perhaps the most revolutionary recent development, harnesses the patient's own immune system to recognize and attack…
